Ferring and Merck Sharp and Dohme have announced the completion of a landmark study assessing a promising new treatment for postpartum haemorrhage (PPH).
The CHAMPION study has enrolled nearly 30,000 women in ten countries, and represents the largest clinical trial ever conducted in PPH. It aims to investigate whether the drug carbetocin could offer a new solution to prevent excessive bleeding after childbirth.
“Ferring and Merck Sharp and Dohme have completed a study assessing a new treatment for postpartum haemorrhage.“
Heat-stable carbetocin has the potential to address a significant limitation associated with oxytocin, the current standard of care, which needs to be kept refrigerated during shipping and storage to prevent degradation.
By contrast, carbetocin can remain active long-term in hot and humid climates, and could potentially reduce the incidence of PPH in areas where cold storage is difficult to achieve and maintain.
If the results of the CHAMPION trial are favourable, Ferring aims to provide the product to public sector bodies in low and lower-middle-income countries at an affordable and sustainable access price.
Professor Klaus Dugi, chief medical officer of Ferring Pharmaceuticals, said: "We are looking forward to seeing the results from the CHAMPION trial and hope that the learnings will usher in a new era in the prevention of PPH."
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical